Samuel Bates Martin, SVP and CFO at Celldex Therapeutics, Inc. (CLDX), bought 9,750 shares at $3.05 ($30K) on 2020-06-09, disclosed to the SEC on 2020-06-10.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| CLDX | SELL | 2022-08-15 | $1.4M | — | Filing → |
| CLDX | SELL | 2021-12-28 | $399K | — | Filing → |
| CLDX | SELL | 2021-11-17 | $828K | — | Filing → |